Home-care companies' offerings take off.
Some home infusion therapy companies have been the beneficiaries of cash infusions thanks to the bullish reception of public offerings this year. The lucrative industry, reimbursed primarily by private payers and one of the fastest growing in healthcare, has long been a favorite on Wall Street. The companies plan to use proceeds from the successful offerings to pay off debt and finance expansion.
Lutz
S
S
D004345:Drug Industry / Q000191:economics*; D004389:Durable Medical Equipment / Q000191:economics; D006699:Home Care Services / Q000191:economics*; D016331:Parenteral Nutrition, Home / Q000191:economics; D014481:United States